Get the Stockscreener App
10.52
2.63%
0.27
Adma Biologics Inc stock is traded at $10.52, with a volume of 4.13M.
It is up +2.63% in the last 24 hours and up +15.48% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$10.25
Open:
$10.28
24h Volume:
4.13M
Relative Volume:
0.72
Market Cap:
$2.44B
Revenue:
$510.17M
Net Income/Loss:
$146.93M
P/E Ratio:
17.56
EPS:
0.599
Net Cash Flow:
$27.51M
1W Performance:
-6.57%
1M Performance:
+15.48%
6M Performance:
-32.04%
1Y Performance:
-54.79%
1-Day Range:
$10.27
$10.56
1-Week Range:
$10.19
$11.33
52-Week Range:
$7.2101
$24.17
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
10.52 | 2.44B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - Barchart
Earnings Preview: ADMA to Report Financial Results Post-market on May 06 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ... - Caledonian Record
ADMA stock downgraded by Cantor as ‘channel stuffing’ claims shake investor confidence - MSN
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vanguard (NASDAQ: ADMA) reports 12.11M shares, 5.08% stake - Stock Titan
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Immunoglobulin Market Leading Players AnalysisADMA - openPR.com
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
Investigation into ADMA Biologics for Potential Securities Fraud - Intellectia AI
ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Research - MarketBeat
ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA ... - Caledonian Record
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Yahoo Finance
ADMA Biologics Investor News: If You Have Suffered Losses - GlobeNewswire
ADMA Biologics rejects claims made in short-seller report - MSN
ADMA Biologics drops amid short report from Culper Research - MSN
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
Q2 2025 ADMA Biologics Inc Earnings Call Transcript - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: Could an 83% Potential Upside Be Within Reach? - DirectorsTalk Interviews
ADMA Biologics gains after refuting short seller claims - MSN
Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA) - Yahoo Finance
Does ADMA Biologics' growth story outweigh short-seller concerns? - MSN
ADMA stock drops 6% after Culper Research alleges channel stuffing - MSN
Down 27% in 4 weeks, here's why Adma Biologics (ADMA) looks ripe for a turnaround - MSN
MSN Money - MSN
Wall Street Zen Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy - MarketBeat
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
Precision Trading with Adma Biologics Inc (ADMA) Risk Zones - Stock Traders Daily
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends - Insider Monkey
ADMA Legal Notification: ADMA Biologics Securities Class - GlobeNewswire
Is ADMA Biologics (ADMA) Falling Share Price Creating A Potential Opportunity For Investors - simplywall.st
ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - TMX Newsfile
Top 10 AI-Powered Biotech Stocks to Buy Right Now - Insider Monkey
ADMA Biologics Inc (ADMA) posts six percent Q4 2025 EPS beat, shares climb 0.85 percent in today’s session. - Xã Thanh Hà
ADMA Biologics Inc (ADMA) delivers Q4 2025 EPS beat, shares rise 2.51 percent on positive investor sentiment.Meme Stock - Cổng thông tin điện tử tỉnh Lào Cai
ADMA Biologics Inc (ADMA) posts Q4 2025 EPS above analyst forecasts, shares rise modestly on positive investor sentiment.Most Watched Stocks - UBND thành phố Hải Phòng
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):